Status:
COMPLETED
Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia
Lead Sponsor:
Ain Shams University
Conditions:
Glycemic Control
Insulin
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The role of ultralong insulin in the control of the blood glucose level in diabetic patients is well known, the current study will discuss the role of ultralong insulin in controlling of hyperglycaemi...
Detailed Description
A standard monitor will be attached to the patients including 5 leads ECG, pulse oximeter, NIBP and IV line will be secured. The hemodynamic parameters will be recorded every 15 minutes. The random b...
Eligibility Criteria
Inclusion
- Patients with Blood glucose level \>250 mg/dl for more than 24 h
Exclusion
- Age less than 18 or greater than 60 years
- Diabetic Ketoacidosis
- Patients with recurrent episodes of hypoglycaemia-\* Stress hyperglycemia
- Patients refusing to participate in the study.
- Patients with renal insufficiency
- Patients on corticosteroids
Key Trial Info
Start Date :
December 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2024
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06178874
Start Date
December 1 2023
End Date
June 1 2024
Last Update
August 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain shams university
Cairo, Egypt, 12245